TwitterRSSFacebookDirectors Blog
  Disorders A - Z:   A    B   C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

Skip secondary menu

Funding News - Applications for Specialized Programs of Translational Research in Acute Stroke Sought

Archive folder iconHistorical Data

  • The information on this page is for historical and research purposes only.
  • For the most current NINDS funding announcements, please see the NINDS list of Active Funding Initiatives or Follow Us on Twitter for the latest funding news.

The National Institute of Neurological Disorders and Stroke (NINDS) encourages grant applications for Specialized Programs of Translational Research in Acute Stroke (SPOTRIAS).* The goal of the SPOTRIAS will be to reduce the disability of and mortality in stroke patients by promoting rapid diagnosis and effective intervention. The intent of the programs is to support a collaboration of clinical research from different specialties whose collective efforts will lead to new approaches for early diagnosis and treatment of acute stroke patients. Despite enormous research efforts including many clinical trials, tissue plasminogen activator (tPA) remains the only FDA-approved treatment for acute ischemic stroke. The requirement for administration within 3 hours of stroke onset has proven a major obstacle to the widespread use of tPA. Dramatic improvements in stroke outcomes could be achieved by reducing the time necessary to respond to and diagnose stroke and by identifying new interventions that could be safely and promptly administered to a wider range of patients. Examples of potential research include: studies to evaluate novel stroke treatments; development and testing of innovative systems for delivery of emergency medical services; development and evaluation of clinical tools useful for rapid stroke treatment; tests of potential biomarkers, surrogate outcomes, and clinical stroke scales useful in acute stroke research; development and evaluation of new treatments and practices within critical care units for patients immediately after initial emergency department management; tests of strategies for rehabilitation of acute stroke patients; and long-term quality-of-life research for patients treated early for acute stroke. For more information, potential applicants should contact Dr. John Marler, Associate Director for Clinical Trials, NINDS, Neuroscience Center, 6001 Executive Boulevard, Room 2216, Bethesda, MD 20892; telephone: (301) 496-9135; fax: (301) 480-1080; e-mail:

*For a more detailed description of this program announcement, please visit the NIH web site at: